Navigation Links
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
Date:5/14/2008

ancing from leading venture capital firms ARCH Venture Partners, Polaris Venture Partners, Venrock and OVP, all of which have built some of the world's leading life sciences companies, and additional investors. The company's board of directors includes Amir Nashat, general partner, Polaris Venture Partners; Robert Nelsen, co-founder and managing director, ARCH Venture Partners; and Bryan Roberts, managing general partner, Venrock. Nelsen and Roberts were named to the Forbes 2008 Midas List of the top 100 tech deal makers in the world.

"Fate has brought together the best minds in science with the top business minds in biotech," said Alex Rives, founding president of Fate. "Paul Grayson and John Mendlein are respected biotechnology executives with a history of developing breakthrough pharmaceuticals and innovative business strategies. Their leadership is the next step in creating an entirely new therapeutic paradigm for non-embryonic or adult stem cell medicine."

About Fate Therapeutics

Fate Therapeutics is a privately held biopharmaceutical company pioneering the field of renewal therapies, a newly emerging area of research and drug development. Founded by a world-class collaborative team of luminaries in the science of adult stem cell biology, management with a proven track record in translating new science into innovative drug and business opportunities, and an investor syndicate with an unparalleled history of establishing and advancing revolutionary biotechnology companies, Fate is working to launch a new era of medicine with the potential to offer new hope to patients afflicted with some of the most difficult to treat conditions, including degenerative diseases such as diabetes, Parkinson's and Alzheimer's Disease, ALS, heart failure, stroke and paralysis; developmental disorders including Down syndrome; and metastatic cancers.

For more information, see http://www.fatetherapeutic
'/>"/>

SOURCE Fate Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
2. Amicus Therapeutics Announces First Quarter 2008 Financial Results
3. Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
5. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
6. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
7. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
8. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
9. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Inc. (NASDAQ: GNVC ) today announced the retirement ... of directors effective on October 24, 2014.   Dr. Horovitz joined ... chairman from June 2006 to November 2013.  During his tenure, ... Audit Committees of the board.  "We deeply ... to GenVec, and its stockholders," said Wayne T. Hockmeyer ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... June 30 Celsis In Vitro, Inc. (Celsis ... infringement lawsuit against Invitrogen Corporation (Invitrogen) and CellzDirect, Inc. ... Northern District of Illinois in Chicago ... the parent of CellzDirect, is itself a wholly-owned subsidiary ...
... showcasing pharmaceutical, biotechnological and medical device employers in areas ranging from Niagara Falls to ... (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the ...
... TargeGen, Inc., a privately held biotechnology company focused on ... the Company has agreed to be acquired by sanofi-aventis (EURONEXT: ... will depend on the achievement of certain future milestones events ... fully realized. The closing of the transaction is expected to ...
Cached Biology Technology:Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement 2Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement 3BioSpace Promotes the Northeast Corridor's Life Science Industry 2BioSpace Promotes the Northeast Corridor's Life Science Industry 3Sanofi-aventis to Acquire TargeGen, Inc. 2
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... mating systems, reproductive success reflects phenotypic variation. At ... that of body size and weapon morphology, as ... In a study published in the September issue ... Arizona University) and Jerry F. Husak (Oklahoma State ...
... step toward developing a new type of ultra-sensitive medical ... the skin to detect tiny gold nanorods injected into ... yielded images nearly 60 times brighter than conventional fluorescent ... of biological imaging to study the inner workings of ...
... "shooting stars" of their field. Many research scientists have been ... the blood into diseased organs and replace defective tissue. Such ... of certain muscle diseases. However, a study currently being conducted ... the cells are able to migrate into the muscle fibres, ...
Cached Biology News:Purdue's gold nanorods brighten future for medical imaging 2Research casts doubt on circulating stem cells 2Research casts doubt on circulating stem cells 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... short-term enriched housing for nonhuman primates and ... non-quarantine settings on a per diem basis. ... state-of-the-art social housing and nursery facilities. In ... CDC quarantine facilities. Primate housing and ...
... some the things youll be telling others after ... by Erica Golemis, One look at the table ... topics in protein interaction will tell you immediately ... a part of your personal protein chemistry library. ...
Biology Products: